Central orexin-A augments sympathoadrenal outflow in conscious rabbits

Kiyoshi Matsumura, Takuya Tsuchihashi, Isao Abe

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

We determined the cardiovascular and neurohormonal responses to intracerebroventricular administration of orexin-A in conscious rabbits. Intracerebroventricular injection of orexin-A elicited dose-related increases in mean arterial pressure and renal sympathetic nerve activity. Peak values of mean arterial pressure and renal sympathetic nerve activity induced by intracerebroventricular injection of 100 pmol of orexin-A (14.0±0.7 mm Hg and 55.4±14.9%, respectively) were obtained at 40 and 25 minutes after injection, respectively. Plasma epinephrine and glucose concentrations were significantly increased at 60 and 90 minutes after intracerebroventricular injection of orexin-A (control versus 90 minutes; for epinephrine, 38.0±12.8 versus 167.5±42.5 pg/mL, P<0.01; for glucose, 6.66±0.18 versus 7.75 ±0.14 mmol/L, P<0.01). Plasma norepinephrine and insulin concentrations increased at 60 and 90 minutes but did not attain significant values. Intracerebroventricular injection of orexin-A also caused significant increases in plasma vasopressin concentrations. However, pretreatment with an intravenous injection of pentolinium (5 mg/kg), a ganglion-blocking agent, abolished these cardiovascular and neurohormonal responses. On the other hand, intravenous injection of the same dose of orexin-A (100 pmol) used in the intracerebroventricular experiment failed to cause any cardiovascular and renal sympathetic nerve responses. These results suggest that intracerebroventricular orexin-A acts in the central nervous system and activates sympathoadrenal outflow, resulting in increases in arterial pressure and plasma glucose levels in conscious rabbits.

Original languageEnglish
Pages (from-to)1382-1387
Number of pages6
JournalHypertension
Volume37
Issue number6
DOIs
Publication statusPublished - Jan 1 2001

Fingerprint

Rabbits
Injections
Arterial Pressure
Kidney
Glucose
Intravenous Injections
Epinephrine
Pentolinium Tartrate
Cardiovascular Agents
Orexins
Vasopressins
Ganglia
Norepinephrine
Central Nervous System
Insulin

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Central orexin-A augments sympathoadrenal outflow in conscious rabbits. / Matsumura, Kiyoshi; Tsuchihashi, Takuya; Abe, Isao.

In: Hypertension, Vol. 37, No. 6, 01.01.2001, p. 1382-1387.

Research output: Contribution to journalArticle

Matsumura, Kiyoshi ; Tsuchihashi, Takuya ; Abe, Isao. / Central orexin-A augments sympathoadrenal outflow in conscious rabbits. In: Hypertension. 2001 ; Vol. 37, No. 6. pp. 1382-1387.
@article{a3fa1143c1d3498a9bfed3aa3f3ec90b,
title = "Central orexin-A augments sympathoadrenal outflow in conscious rabbits",
abstract = "We determined the cardiovascular and neurohormonal responses to intracerebroventricular administration of orexin-A in conscious rabbits. Intracerebroventricular injection of orexin-A elicited dose-related increases in mean arterial pressure and renal sympathetic nerve activity. Peak values of mean arterial pressure and renal sympathetic nerve activity induced by intracerebroventricular injection of 100 pmol of orexin-A (14.0±0.7 mm Hg and 55.4±14.9{\%}, respectively) were obtained at 40 and 25 minutes after injection, respectively. Plasma epinephrine and glucose concentrations were significantly increased at 60 and 90 minutes after intracerebroventricular injection of orexin-A (control versus 90 minutes; for epinephrine, 38.0±12.8 versus 167.5±42.5 pg/mL, P<0.01; for glucose, 6.66±0.18 versus 7.75 ±0.14 mmol/L, P<0.01). Plasma norepinephrine and insulin concentrations increased at 60 and 90 minutes but did not attain significant values. Intracerebroventricular injection of orexin-A also caused significant increases in plasma vasopressin concentrations. However, pretreatment with an intravenous injection of pentolinium (5 mg/kg), a ganglion-blocking agent, abolished these cardiovascular and neurohormonal responses. On the other hand, intravenous injection of the same dose of orexin-A (100 pmol) used in the intracerebroventricular experiment failed to cause any cardiovascular and renal sympathetic nerve responses. These results suggest that intracerebroventricular orexin-A acts in the central nervous system and activates sympathoadrenal outflow, resulting in increases in arterial pressure and plasma glucose levels in conscious rabbits.",
author = "Kiyoshi Matsumura and Takuya Tsuchihashi and Isao Abe",
year = "2001",
month = "1",
day = "1",
doi = "10.1161/01.HYP.37.6.1382",
language = "English",
volume = "37",
pages = "1382--1387",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Central orexin-A augments sympathoadrenal outflow in conscious rabbits

AU - Matsumura, Kiyoshi

AU - Tsuchihashi, Takuya

AU - Abe, Isao

PY - 2001/1/1

Y1 - 2001/1/1

N2 - We determined the cardiovascular and neurohormonal responses to intracerebroventricular administration of orexin-A in conscious rabbits. Intracerebroventricular injection of orexin-A elicited dose-related increases in mean arterial pressure and renal sympathetic nerve activity. Peak values of mean arterial pressure and renal sympathetic nerve activity induced by intracerebroventricular injection of 100 pmol of orexin-A (14.0±0.7 mm Hg and 55.4±14.9%, respectively) were obtained at 40 and 25 minutes after injection, respectively. Plasma epinephrine and glucose concentrations were significantly increased at 60 and 90 minutes after intracerebroventricular injection of orexin-A (control versus 90 minutes; for epinephrine, 38.0±12.8 versus 167.5±42.5 pg/mL, P<0.01; for glucose, 6.66±0.18 versus 7.75 ±0.14 mmol/L, P<0.01). Plasma norepinephrine and insulin concentrations increased at 60 and 90 minutes but did not attain significant values. Intracerebroventricular injection of orexin-A also caused significant increases in plasma vasopressin concentrations. However, pretreatment with an intravenous injection of pentolinium (5 mg/kg), a ganglion-blocking agent, abolished these cardiovascular and neurohormonal responses. On the other hand, intravenous injection of the same dose of orexin-A (100 pmol) used in the intracerebroventricular experiment failed to cause any cardiovascular and renal sympathetic nerve responses. These results suggest that intracerebroventricular orexin-A acts in the central nervous system and activates sympathoadrenal outflow, resulting in increases in arterial pressure and plasma glucose levels in conscious rabbits.

AB - We determined the cardiovascular and neurohormonal responses to intracerebroventricular administration of orexin-A in conscious rabbits. Intracerebroventricular injection of orexin-A elicited dose-related increases in mean arterial pressure and renal sympathetic nerve activity. Peak values of mean arterial pressure and renal sympathetic nerve activity induced by intracerebroventricular injection of 100 pmol of orexin-A (14.0±0.7 mm Hg and 55.4±14.9%, respectively) were obtained at 40 and 25 minutes after injection, respectively. Plasma epinephrine and glucose concentrations were significantly increased at 60 and 90 minutes after intracerebroventricular injection of orexin-A (control versus 90 minutes; for epinephrine, 38.0±12.8 versus 167.5±42.5 pg/mL, P<0.01; for glucose, 6.66±0.18 versus 7.75 ±0.14 mmol/L, P<0.01). Plasma norepinephrine and insulin concentrations increased at 60 and 90 minutes but did not attain significant values. Intracerebroventricular injection of orexin-A also caused significant increases in plasma vasopressin concentrations. However, pretreatment with an intravenous injection of pentolinium (5 mg/kg), a ganglion-blocking agent, abolished these cardiovascular and neurohormonal responses. On the other hand, intravenous injection of the same dose of orexin-A (100 pmol) used in the intracerebroventricular experiment failed to cause any cardiovascular and renal sympathetic nerve responses. These results suggest that intracerebroventricular orexin-A acts in the central nervous system and activates sympathoadrenal outflow, resulting in increases in arterial pressure and plasma glucose levels in conscious rabbits.

UR - http://www.scopus.com/inward/record.url?scp=0035571117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035571117&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.37.6.1382

DO - 10.1161/01.HYP.37.6.1382

M3 - Article

C2 - 11408381

AN - SCOPUS:0035571117

VL - 37

SP - 1382

EP - 1387

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 6

ER -